Back to results
US 2022/0177595 A1Published application
Multimeric gitr binding molecules and uses thereof
AssigneeIGM Biosciences, Inc.
InventorsBeatrice Tien-Yi WANG, Bruce Alan KEYT, Ramesh BALIGA
Life of this patent
Estimating the term…
Abstract
This disclosure provides dimeric, pentameric, and hexameric GITR agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
Claims46
A multimeric binding molecule comprising two, five, or six bivalent binding units or variants or fragments thereof,
- wherein each binding unit comprises two IgA or IgM heavy chain constant regions or fragments thereof, each associated with an antigen-binding domain,
- wherein at least three of the antigen-binding domains of the binding molecule can specifically and agonistically bind to a GITR monomer on a cell expressing GITR, and
- wherein the binding molecule can induce GITR-mediated signal transduction in the cell in the absence of a secondary cross-linking moiety.
Dependencies are inferred from the claim text.